Bladder cancer stage 0 with cancer in situ – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:41 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bladder cancer stage 0 with cancer in situ – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of ONCOFID-P-B for Patients with Bladder Carcinoma in Situ Unresponsive to BCG Treatment https://clinicaltrials.eu/trial/study-of-oncofid-p-b-for-patients-with-bladder-carcinoma-in-situ-unresponsive-to-bcg-treatment/ Wed, 29 Apr 2026 14:29:31 +0000 https://clinicaltrials.eu/trial/study-of-oncofid-p-b-for-patients-with-bladder-carcinoma-in-situ-unresponsive-to-bcg-treatment/ This clinical trial is focused on studying a condition known as Carcinoma in Situ of the bladder, which is a type of bladder cancer that has not responded to the standard treatment called BCG therapy. The study is investigating a new treatment called ONCOFID-P-B, which is a special formulation of a drug named paclitaxel obaluronate. This treatment is administered directly into the bladder, a method known as intravesical administration. The main goal of the study is to evaluate how effective and safe this new treatment is for patients who have not had success with previous therapies.

Participants in the study will receive the ONCOFID-P-B treatment over a period of time, and their response to the treatment will be closely monitored. The study will look at how many patients achieve a complete response, meaning no signs of cancer are detected, at various points during the study. The study will also track how long the response lasts, whether the cancer progresses, and the overall survival of the participants. Some patients may receive a placebo, which is a substance with no active drug, to compare the effects of the new treatment.

The study is designed to provide valuable information about the potential benefits of ONCOFID-P-B for patients with Carcinoma in Situ of the bladder who have not responded to BCG therapy. By participating in this study, researchers hope to find a new and effective treatment option for this challenging condition. The study is expected to continue until 2030, allowing for comprehensive data collection and analysis.

]]> Study on the Safety and Effectiveness of TARA-002 for Adults with High-Grade Non-Muscle Invasive Bladder Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tara-002-for-adults-with-high-grade-non-muscle-invasive-bladder-cancer/ Wed, 29 Apr 2026 14:26:59 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tara-002-for-adults-with-high-grade-non-muscle-invasive-bladder-cancer/ This clinical trial is focused on studying a type of bladder cancer known as high-grade non-muscle invasive bladder cancer. The treatment being tested is called TARA-002, which is a form of inactivated bacteria known as Streptococcus pyogenes. This treatment is administered directly into the bladder through a process called intravesical instillation, which involves placing the medication directly into the bladder.

The purpose of the study is to evaluate the safety and effectiveness of TARA-002 in treating this type of bladder cancer. Participants in the study will receive the treatment and will be monitored for any changes in their condition. The study will also look at how the treatment affects the cancer and any side effects that may occur. The study is divided into two groups, with each group receiving the treatment and undergoing regular check-ups to assess the treatment’s impact on their cancer.

Throughout the study, participants will have regular medical evaluations, including procedures like cystoscopy (a test that allows doctors to look inside the bladder), bladder biopsies (taking a small sample of bladder tissue for testing), and urine tests. These evaluations will help determine how well the treatment is working and ensure the safety of the participants. The study aims to provide valuable information on the potential benefits of TARA-002 for people with high-grade non-muscle invasive bladder cancer.

]]>